Objective To evaluate the efficacy and safety of rh-endostatin(endostar) combined with FOLFIRI regimen in colorectal cancer with hepatic metastasis. Methods Twenty-nine patients with hepatic metastasis of colorectal cancer were treated with endostar and FOLFIRI regimen from September 2006 to January 2011. Endostar 15mg solved in 500ml normal saline was slowly intravenously dropped from day 1 to day 10 biweekly. FOLFIRI regimen; irinotecan 180mg/m2 iv, d1; leucovorin 400mg/m2 introvenous infusion to match duration of irinotecan infusion, d1 ; fluorouracil 400mg/m2 iv bolus d, , and then 2400mg/m2 for46-8h continuously infusion. Every 2 weeks was a cycle. The safety was evaluated after 1 cycle while the efficacy was evaluated after 3-4 cycles. Results All the cases were evaluated for safety and 27 cases for efficacy with 1 of CR, 10 of PR, 9 of SD and 7 of PD. The response rate was 40. 7% and disease control rate was 74. 1%. The quality of life in 14 cases was improved. The median progress-free survival was 7. 8 months(95% CI :5. 3-10. 2 months). The adverse effects were mainly in grade 1 -2, including hematological toxicities, nausea and vomiting and tardive diarrhea. There was no serious event in cardiovascular system. Conclusion The efficacy and tolerability of endostar plus FOLFIRI regimen in hepatic metastasis of colorectal cancer was good with tolerable adverse effect.%目的 探讨重组人血管内皮抑素(恩度)联合FOLFIRI方案治疗结直肠癌肝转移的疗效和安全性.方法 收集2006年9月至2011年1月29例结直肠癌肝转移患者,给予恩度联合FOLFIRI方案治疗.恩度15mg静滴,d1～d10,14天为1周期.FOLFIRI方案:伊立替康180mg/m2静滴,d1；亚叶酸钙400mg/m2静滴,d1；氟尿嘧啶400mg/m2静推,d1,2400mg/m2持续静滴46 ～48h,14天为1周期.每周期评价不良反应,3～4个周期评价疗效.结果 29例患者中有27例可评价疗效,获CR 1例,PR 10例,SD 9例,PD 7例,有效率为40.7％,疾病控制率为74.1％,14例患者生活质量改善；全组有27例获随访,中位无进展生存期为7.8个月(95％CI:5.3 ～ 10.2个月).毒副反应主要为血液学毒性、恶心呕吐和迟发性腹泻,以1～2级为主,未出现严重的心血管系统毒副反应.结论 恩度联合FOLFIRI方案治疗结直肠癌肝转移疗效较好,毒副反应可耐受.
展开▼
